Ligand Pharmaceuticals (LGND) EBIT Margin Growth (3y) (2013 - 2026)

Ligand Pharmaceuticals (LGND) EBIT Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,942.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Ligand Pharmaceuticals 6.05 Bn 5.27 Bn 48.45 Mn 128.00

Historic Data

Download Data
DateValue
Mar 31, 2026 128.00
Dec 31, 2025 6,309.00
Sep 30, 2025 2,674.00
Jun 30, 2025 45.00
Mar 31, 2025 -8,573.00
Dec 31, 2024 -8,933.00
Sep 30, 2024 -2,024.00
Jun 30, 2024 -10,399.00
Mar 31, 2024 -47.00
Dec 31, 2023 -4,462.00
Sep 30, 2023 41.00
Jun 30, 2023 -2,466.00
Mar 31, 2023 2,088.00
Dec 31, 2022 -220.00
Sep 30, 2022 4,163.00
Jun 30, 2022 3,381.00
Mar 31, 2022 -189,496.00
Dec 31, 2021 1,119.00
Sep 30, 2021 -2,485.00
Jun 30, 2021 -1,993.00